Genetic therapy for vein bypass graft disease: Current perspectives

Vascular

Volumn 12, Issue 4, 2004, Pages 213-217

  Simosa, Hector F ^a   Conte, Michael S ^a,b  

^a Harvard Institute for Human Genetics   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gene expression; Gene transfer; Genetic vectors; Oligonucleotides; Vein bypass graft

Indexed keywords

TRANSCRIPTION FACTOR E2F;

ARTERY DISEASE; AUTOGRAFT; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE DELIVERY SYSTEM; GENE THERAPY; GRAFT FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; REVIEW; THROMBOSIS; UNITED STATES; VASCULAR PATENCY; VEIN BYPASS; VEIN BYPASS GRAFT; VEIN GRAFT;

EID: 9644281027     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1258/rsmvasc.12.4.213     Document Type: Review

References (19)

1. Belkin M, Whittemore AD. Infrainguinal bypass. In: Rutherford RB, editor. Vascular surgery. 5th ed. Philadelphia: WB Saunders Company; 2000. p. 998-1018.
2. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-32.
3. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-10.
4. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7:33-40.
5. Pierre-Paul D, Gahtan V, Conte MS. Molecular biology and gene therapy in vascular disease. In: Rutherford RB, editor. Vascular surgery. 6th ed. Philadelphia: Elsevier Science Inc.; 2004. [In press].
6. Colman A. Antisense strategies in cell and developmental biology. J Cell Sci 1990;97:399-409.
7. Askari F, McDonnell W. Molecular medicine: antisense oligonucleotide therapy. N Engl J Med 1996;334:316-8.
8. Zaug A, Been M, Cech T. The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature 1986;324:429-33.
9. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11.
10. Bielinska A, Schivdasani R, Zhang L. Regulation of gene expression with double-stranded phosphothioate oligonucleotides. Science 1990;250:997-1000.
11. Mann MJ, Conte MS. Transcription factor decoys for the prevention of vein graft failure. Am J Cardiovasc Drugs 2003;3:79-85.
12. Towne JB. The autogenous vein. In: Rutherford RB, editor. Vascular surgery. Philadelphia: WB Saunders; 1995. p. 482-91.
13. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991;34:45-68.
14. Conte MS, Mann MJ, Simosa HF, et al. Genetic interventions for vein bypass graft disease: a review. J Vasc Surg 2002;36:1040-52.
15. Morishita R, Gibbons GH, Horiuchi M, et al. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995;92:5855-9.
16. Mann MJ, Kernoff R, Dzau VJ. Vein graft gene therapy using E2F decoy oligonucleotides: target gene inhibition in human veins and long-term resistance to atherosclerosis in rabbits. Surg Forum 1997;48:242-4.
17. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001;121:714-22.
18. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999;354:1493-8.
19. Grube E, Felderhoff T, Fitzgerald PJ, et al. PREVENT II: results of E2F decoy treatment of coronary vein bypass grafts. In: American Heart Association (late breaking clinical trials). Anaheim (CA): 2001. [Unpublished abstract].